Guest column : Can Indian generics move from blockbusters to biologics?

For generic dug manufacturers in India and elsewhere the number of blockbuster drugs that have recently come off patent has been a bonanza. But the product mix coming off patent over the next three years is dramatically different to the small molecule blockbuster drugs that dominated patent expirations in 2012. This presents a problem for them. Continue reading “Guest column : Can Indian generics move from blockbusters to biologics?”